Sugawara Atsushi, Torigoe Toshihiko, Tamura Yasuaki, Kamiguchi Kenjiro, Nemoto Kyuichi, Oguro Hiroshi, Sato Noriyuki
Department of Pathology, Sapporo Medical University School of Medicine, Chuo-ku, Sapporo, Japan.
Cell Stress Chaperones. 2009 Mar;14(2):133-9. doi: 10.1007/s12192-008-0064-y. Epub 2008 Aug 7.
Polyamine compound deoxyspergualin (DSG) is a potent immunosuppressive agent that has been applied clinically for protecting graft rejection and treatment of Wegener's granulomatosis. Though DSG can bind to heat-shock proteins (HSPs) in cells, its mechanism of immunosuppressive action remains unknown. It is widely accepted that extracellular HSPs are capable of stimulating dendritic cells (DC) through cell surface receptors, leading to DC activation and cytokine release. In this study, we examined if DSG analogs could inhibit HSP70-induced DC activation. Bone marrow derived immature mouse DCs and peripheral blood mononuclear cell-derived immature human DCs were generated and incubated with Alexa 488-labeled Hsp70 in the presence of methoxyDSG (Gus-1) that had comparable HSP70-binding affinity to DSG or DSG analog GUS-7, which had much more reduced binding affinity for HSP70. The binding of HSP70 to immature DCs was analyzed by laser microscopy and flow cytometry. HSP70-induced DC activation was assessed by TNF-alpha release by enzyme-linked immunosorbent assay. Binding of Hsp70 to the cell surface of immature DCs was inhibited under the presence of Gus-1, but not under the presence of Gus-7. Immature DCs were activated and released TNF-alpha by the stimulation with HSP70 for 12 hours; however, the HSP70-induced TNF-alpha release was suppressed under the presence of Gus-1, and partially suppressed under the presence of Gus-7. Similar results were observed when immature human DCs were stimulated under the same conditions. Immunosuppressive mechanism of DSG may be explained, at least in part, by the inhibition of extracellular HSP70-DC interaction and HSP70-induced activation of immature DCs.
多胺化合物去氧精胍菌素(DSG)是一种强效免疫抑制剂,已在临床上用于预防移植排斥反应和治疗韦格纳肉芽肿。尽管DSG可与细胞中的热休克蛋白(HSPs)结合,但其免疫抑制作用机制仍不清楚。人们普遍认为,细胞外HSPs能够通过细胞表面受体刺激树突状细胞(DC),导致DC活化和细胞因子释放。在本研究中,我们检测了DSG类似物是否能抑制HSP70诱导的DC活化。制备了骨髓来源的未成熟小鼠DC和外周血单核细胞来源的未成熟人DC,并在甲氧基DSG(Gus-1)存在的情况下与Alexa 488标记的Hsp70一起孵育,Gus-1与DSG具有相当的HSP70结合亲和力,或DSG类似物GUS-7,其对HSP70的结合亲和力大大降低。通过激光显微镜和流式细胞术分析HSP70与未成熟DC的结合。通过酶联免疫吸附测定法检测TNF-α释放来评估HSP70诱导的DC活化。在Gus-1存在下,Hsp70与未成熟DC细胞表面的结合受到抑制,但在Gus-7存在下则不受抑制。未成熟DC通过HSP70刺激12小时后被激活并释放TNF-α;然而,在Gus-1存在下,HSP70诱导的TNF-α释放受到抑制,在Gus-7存在下部分受到抑制。在相同条件下刺激未成熟人DC时也观察到了类似结果。DSG的免疫抑制机制至少部分可以通过抑制细胞外HSP70-DC相互作用和HSP70诱导的未成熟DC活化来解释。